Elaia, a leading European venture capital firm, has successfully closed its third deep tech seed fund, DTS3, at €134 million, which is noteworthy for being significantly larger than its previous funds. The fund is a collaboration with esteemed European research organizations such as PSL, INRIA, CNRS, the Barcelona Supercomputing Centre, and the Max Planck Foundation. The firm’s notable objective is to facilitate entrepreneurial advancements within deep technology by channeling substantial investment into seed-stage startups across Europe, with an emphasis on transformational innovations in various sectors. These sectors include computing, life sciences, and industrial enhancement, marking Elaia’s commitment to addressing key technological bottlenecks.
Elaia has consistently engaged with European research leaders to anticipate technological breakthroughs, setting grounds for ambitious startups. Previous ventures by Elaia have focused on fostering firms that drive commercial fusion, regenerative medicine, and data analysis breakthroughs. This historical focus reflects a continuity in Elaia’s approach to prioritize high-impact sectors, leveraging its network to harness significant advancements in technology and life sciences.
What is DTS3’s Investment Strategy?
With DTS3, Elaia focuses on nurturing pre-seed and seed-stage B2B startups by investing between €1 million and €13 million. This initiative is targeted at early-stage entrepreneurs throughout Europe. By collaborating with founders at the nascent stages of their journey, Elaia aims to support enterprises tackling central challenges in next-generation infrastructure, as exemplified by its backing of Proxima Fusion in Germany, and GetVocal and Biophta in France.
How Does Elaia Foster European Deep Tech Ambitions?
Elaia’s Partner, Anne-Sophie Carrese, affirms that the venture’s partnerships with top-tier research bodies enable early access to cutting-edge technologies. She believes that the innovation impetus in Europe currently matches global ecosystems.
“These partnerships with Europe’s top research institutions give us early visibility into breakthrough technologies and exceptional founding teams. After nearly two decades backing deep tech founders, we’re seeing an acceleration of innovation that rivals any ecosystem in the world.”
Xavier Lazarus, Managing Partner, shares that DTS3 embodies Elaia’s ambition to support European founders. He notes their active investor network mirrors their geographic focus.
“DTS3 reflects our international ambition: we’re backing founders across Europe, and our growing investor network reflects this geographic mix.”
The latest fund has already facilitated investments in 11 companies and prospects to deploy more capital in the upcoming years. DTS3’s strategy is focused on the future of multiple sectors, including computing, industry, and life sciences, highlighting the diverse scope of deep tech investment.
Continuing its strategic advancement, Elaia is poised to significantly enhance European deep tech capabilities across various domains. The fund’s deployment strategy addresses substantial opportunities within AI, robotics, and health technology sectors. As these investments grow, they offer the potential to underpin transformative business models, equipping startups to scale effectively. By aligning its funds with prominent research partnerships, Elaia aims to ensure a steady pipeline of innovation and solidify its footprint as a facilitator of technological advancement. This focused approach may pave the way for emerging leaders to spearhead transformative shifts within their respective fields, delivering substantial socioeconomic impact across Europe.
